In a recent study published in the iScience journal, researchers assessed the efficiency of immunization with a bacterial peptide conjugated to the severe acute respiratory syndrome coronavirus 2 ...
KLOSTERNEUBURG, Austria & ROCKVILLE, Md.--(BUSINESS WIRE)--VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics ...
Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs ...
Researchers from Elpiscience Biopharmaceuticals Inc. discussed the discovery and preclinical characterization of a novel NKG2A antibody-IL-2 mutant fusion protein – ES-015.129 – being developed as ...
Researchers from MD Anderson Cancer Center recently presented the discovery and preclinical evaluation of LLO-CD47, a novel protein-antibody conjugate linking anti-CD47 to Listeriolysin O (LLO), a ...
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the presentation of preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback